Icagen Pops on Pfizer Buyout Buzz: Pain and More on Table
Shares of Icagen Inc. popped more than 150 percent in early trading Monday on news that the biotech is engaged in preliminary buyout discussions with long-time partner Pfizer Inc.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.